SynchroPET

We build the smallest Positron Emission Tomography (PET) Scanners in medical imaging and research. Our first device promises to disrupt the nuclear imaging market by providing a non invasive input function that makes all PET scanners more quantitative and better at diagnosis and treatment of diseases like cancer, alzheimers, and parkinson's. This new quantitative data opens up and accelerates new possibilities in personalized medical treatments and cures.

SynchroPET headquartered in New York, United States, North America, operates in the Biotechnology, Health Care, Medical Device, Health Diagnostics sector. The company focuses on Biotechnology and has secured $94.4M in funding across 64 round(s). With a team of 1-10 employees, SynchroPET is actively contributing to advancements in Biotechnology. Their latest funding round, Seed Round - SynchroPET, raised $725.0K. Discover more about their projects, partnerships, and impact on our platform.